arrow
A

Andrea Rivas

State University System of Florida
H指数:13
被引数:594

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clopidogrel-Mediated P2Y12 Inhibition According to Renal Function in Patients With Diabetes Mellitus and CAD

根据糖尿病和冠心病患者的肾功能,氯吡格雷介导的P2Y12抑制

2024-07-010
OA
P2Y12 Inhibition in Patients Requiring Oral Anticoagulation After Percutaneous Coronary Intervention The SWAP-AC-2 Study
2024-04-014
PRE
Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention The Switching Antiplatelet-6 (SWAP-6) Study
2023-10-016
OAAI
Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study
2023-07-127
PRE
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy
2022-03-3014
PRE
Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease

双途径抑制联合或不联合氯吡格雷与双重抗血小板治疗在动脉粥样硬化性疾病患者中的药效学特征

2022-02-1415
PRE
Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease

慢性肾脏病对糖尿病合并冠心病患者替格瑞洛药效学和药代动力学的影响

2021-06-113
PRE
Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention The OPTIMUS-6 Study

低维持剂量替格瑞洛方案与标准剂量氯吡格雷在既往无重大心血管事件的糖尿病患者择期经皮冠状动脉介入治疗中的药效学和药代动力学OPTIMUS-6研究

2020-10-1315
OAAI
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic Testing
2020-05-0131
OAAI
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study
2020-04-2120
OAAI
Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus Results of the OPTIMUS-5 Study
2019-11-0120
OAAI
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study
2019-08-3016
PREAI
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention Results of the CANTIC Study

坎格雷洛和压碎的替格瑞洛在接受直接经皮冠状动脉介入治疗的ST段抬高型心肌梗死患者中的血小板抑制作用CANTIC研究的结果

2019-04-02118
OAAI